An investigational anti-inflammatory cream from MC2 Therapeutics may offer an improved treatment option for psoriasis patients, according to recently released EU phase 3 trial results.
Investigators compared the efficacy and safety of a combination of betamethasone dipropionate and calcipotriene cream (Wynzora, MC2 Therapeutics) to an approved betamethasone dipropionate and calcipotriene gel (Taclonex, Leo Pharma).
The topical, fixed dose combination of betamethasone dipropionate and calcipotriene cream (0.005%/0.064% w/w) utilizes MC2 Therapeutics’ patented PAD Technology.
PAD Technology allows calcipotriene and betamethasone dipropionate to remain stable in an aqueous form that quickly absorbs into the skin without feeling greasy, according to the company.
During the trial, researchers found the cream met all primary endpoints, including establishing improved quality of life, convenience and efficacy compared to the gel.
“Wynzora Cream takes the treatment experience in daily routines to a new level. Our PAD Technology has enabled an aqueous cream formulation that is designed for high convenience in daily routines illustrated by the positive patient reported treatment convenience and quality of life outcomes in our phase 3 trials. This is a key component of treatment in real life settings,” says Jesper J. Lange, CEO, MC2 Therapeutics.
MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis. mc2therapeutics.com. https://www.mc2therapeutics.com/news/?nid=5df9ddee44c43. Published December 18, 2019. Accessed December 20, 2019.